Emami Ltd.
EMAMILTD · NSE · Consumer Defensive
With a 20% margin of safety, our buy-below price is ₹400.67.
Piotroski F-score 4/9 — quality of earnings & balance sheet.
Investability checklist
- ✓ROE above 15%27.6%
- ✓Low debt (D/E < 0.5)0.06x
- ✓Positive free cash flow
- ✕Revenue growth > 10%-4%
- ✕Earnings growing-12%
- ✓Net margin ≥ 10%20.5%
- ✓Current ratio > 1.52.31
- ✓Below our fair value
- ✓Margin of safety ≥ 20%
- ✕Above 200-day average
- ✕Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 13.46
- ✕Piotroski ≥ 74/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Strengths
- •Strong return on equity (27.6%).
- •Lightly leveraged balance sheet.
- •Healthy profit margin (20.5%).
- •Financially solid — Altman Z 13.46.
Weaknesses
- •Price below its 200-day moving average (downtrend).
Opportunities
- •Trading in our value buy zone versus sector peers.
- •Well off its 52-week high — possible mean-reversion.
- •Trades ~26% below our estimated fair value.
Threats
- •Earnings contracting year on year.
About Emami Ltd.
Emami Limited manufactures and markets personal and healthcare products in India and internationally. The company offers antiseptic cream, body lotion, prickly heat powder, petroleum jelly, soaps, aloe vera gel, and all-season cream under the BoroPlus brand; oil and cool talc products under the Navratna brand; and ayurvedic products for pain management, immunity, digestive health, and bone and joint health, as well as healthcare products comprising hair growth vitalizers, ski
More in Fast Moving Consumer Goods
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.